Lamson Davis W, Plaza Steven M
Coordinator of Oncology, Bastyr University, Kenmore, Washington, USA.
Altern Med Rev. 2003 Aug;8(3):303-18.
Vitamin K, an essential nutrient often associated with the clotting cascade, has been the focus of considerable research demonstrating an anticancer potential. Much of this research has focused on vitamin K3, although vitamins K2 and K1 have also been shown to have anticancer effects. Early studies of vitamin K3 employed an oxidative model to explain the anticancer effects seen in both in vitro and in vivo studies; however, this model does not adequately address the action of vitamins K1 and K2. Recent research has demonstrated the anticancer action of vitamin K may act at the level of tyrosine kinases and phosphatases, modulating various transcription factors such as Myc and Fos. Tyrosine kinases associated with cyclins have also been shown to be affected by vitamin K, which can lead to cell cycle arrest and cell death.
维生素K是一种常与凝血级联相关的必需营养素,一直是大量研究的焦点,这些研究表明它具有抗癌潜力。尽管维生素K2和K1也已被证明具有抗癌作用,但大部分此类研究都集中在维生素K3上。早期对维生素K3的研究采用氧化模型来解释在体外和体内研究中观察到的抗癌作用;然而,该模型并未充分阐明维生素K1和K2的作用机制。最近的研究表明,维生素K的抗癌作用可能在酪氨酸激酶和磷酸酶水平发挥作用,调节诸如Myc和Fos等各种转录因子。与细胞周期蛋白相关的酪氨酸激酶也已被证明会受到维生素K的影响,这可能导致细胞周期停滞和细胞死亡。